• 1
    Devitt JE, To T, Miller AB. Risk of breast cancer in women with breast cysts. CMAJ 1992; 147; 4549.
  • 2
    Jones BM, Bradbeer JW. The presentation and progress of macroscopic breast cysts. Br. J. Surg. 1980; 67; 669671.
  • 3
    Haagensen CD, Bodian CA, Haagensen DE Jr. Breast cancer risk and detection. Philadelphia: W. B. Saunders, 1981.
  • 4
    Roberts MM, Jones V, Elton RA, Fortt RW, Williams S, Gravelle IH. Risk of breast cancer in women with history of benign disease of the breast. Br. Med. J. (Clin. Res. Ed.) 1984; 288; 275278.
  • 5
    Bundred NJ, West RR, Dowd JO, Mansel RE, Hughes LE. Is there an increased risk of breast cancer in women who have had a breast cyst aspirated? Br. J. Cancer 1991; 64; 953955.
  • 6
    Bruzzi P, Dogliotti L, Naldoni C et al. Cohort study of association of risk of breast cancer with cyst type in women with gross cystic disease of the breast. BMJ 1997; 314; 925928.
  • 7
    Dixon JM, McDonald C, Miller WR. Risk of breast cancer in women with palpable breast cysts: a prospective study. Lancet 1999; 353; 17421745.
  • 8
    Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N. Engl. J. Med. 1985; 312; 146151.
  • 9
    Fitzgibbons PL, Henson DE, Hutter RV. Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch. Pathol. Lab. Med. 1998; 122; 10531055.
  • 10
    Page DL, Dupont WD, Jensen RA. Papillary apocrine change of the breast: associations with atypical hyperplasia and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 1996; 5; 2932.
  • 11
    Eusebi V, Casadei GP, Bussolati G, Azzopardi JG. Adenomyoepithelioma of the breast with a distinctive type of apocrine adenosis. Histopathology 1987; 11; 305315.
  • 12
    Simpson JF, Page DL, Dupont WD. Apocrine adenosis—a mimic of mammary carcinoma. Surg. Pathol. 1990; 3; 289299.
  • 13
    Carter DJ, Rosen PP. Atypical apocrine metaplasia in sclerosing lesions of the breast: a study of 51 patients. Mod. Pathol. 1991; 4; 15.
  • 14
    Seidman JD, Ashton M, Lefkowitz M. Atypical apocrine adenosis of the breast: a clinicopathologic study of 37 patients with 8.7-year follow-up. Cancer 1996; 77; 25292537.
  • 15
    Endoh Y, Tamura G, Kato N, Motoyama T. Apocrine adenosis of the breast: clonal evidence of neoplasia. Histopathology 2001; 38; 221224.
  • 16
    Wells CA, McGregor IL, Makunura CN, Yeomans P, Davies JD. Apocrine adenosis: a precursor of aggressive breast cancer? J. Clin. Pathol. 1995; 48; 737742.
  • 17
    Selim AG, Wells CA. Immunohistochemical localisation of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: relation to oestrogen and progesterone receptors. J. Clin. Pathol. 1999; 52; 838841.
  • 18
    Moriya T, Sakamoto K, Sasano H et al. Immunohistochemical analysis of Ki-67, p53, p21, and p27 in benign and malignant apocrine lesions of the breast: its correlation to histologic findings in 43 cases. Mod. Pathol. 2000; 13; 1318.
  • 19
    Eusebi V, Damiani S, Losi L, Millis RR. Apocrine differentiation in breast epithelium. Adv. Anat. Pathol. 1997; 4; 139155.
  • 20
    Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum. Pathol. 1992; 23; 10951097.
  • 21
    O’Malley FP, Bane AL. The spectrum of apocrine lesions of the breast. Adv. Anat. Pathol. 2004; 11; 19.
  • 22
    O’Malley FP, Page DL, Nelson EH, Dupont WD. Ductal carcinoma in situ of the breast with apocrine cytology: definition of a borderline category. Hum. Pathol. 1994; 25; 164168.
  • 23
    Tavassoli FA, Norris HJ. Intraductal apocrine carcinoma: a clinicopathologic study of 37 cases. Mod. Pathol. 1994; 7; 813818.
  • 24
    Scott MA, Lagios MD, Axelsson K, Rogers LW, Anderson TJ, Page DL. Ductal carcinoma in situ of the breast: reproducibility of histological subtype analysis. Hum. Pathol. 1997; 28; 967973.
  • 25
    Leal C, Henrique R, Monteiro P et al. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers. Hum. Pathol. 2001; 32; 487493.
  • 26
    Mossler JA, Barton TK, Brinkhous AD, McCarty KS, Moylan JA, McCarty KSJ. Apocrine differentiation in human mammary carcinoma. Cancer 1980; 46; 24632471.
  • 27
    Abati AD, Kimmel M, Rosen PP. Apocrine mammary carcinoma. A clinicopathologic study of 72 cases. Am. J. Clin. Pathol. 1990; 94; 371377.
  • 28
    D’Amore ES, Terrier-Lacombe MJ, Travagli JP, Friedman S, Contesso G. Invasive apocrine carcinoma of the breast: a long term follow-up study of 34 cases. Breast Cancer Res. Treat. 1988; 12; 3744.
  • 29
    Japaze H, Emina J, Diaz C et al. ‘Pure’ invasive apocrine carcinoma of the breast: a new clinicopathological entity? Breast 2005; 14; 310.
  • 30
    Azzopardi JG. Problems in breast pathology. Philadelphia: W.B. Saunders, 1979.
  • 31
    Frable WJ, Kay S. Carcinoma of the breast. Histologic and clinical features of apocrine tumors. Cancer 1968; 21; 756763.
  • 32
    Eusebi V, Millis RR, Cattani MG, Bussolati G, Azzopardi JG. Apocrine carcinoma of the breast. A morphologic and immunocytochemical study. Am. J. Pathol. 1986; 123; 532541.
  • 33
    Rosen PP. Rosen’s breast pathology, 2nd edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2001.
  • 34
    Haagensen CD. Diseases of the breast, 3rd edn. Philadelphia: W.B. Saunders, 1986.
  • 35
    Eusebi V, Magalhaes F, Azzopardi JG. Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum. Pathol. 1992; 23; 655662.
  • 36
    Mazoujian G, Pinkus GS, Davis S, Haagensen DE Jr. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. Am. J. Pathol. 1983; 110; 105112.
  • 37
    Miller WR, Shivas AA, Franchimont P, Haagensen DE. Breast gross cystic disease protein 15 in human breast cancer in culture. Eur. J. Cancer Clin. Oncol. 1988; 24; 223228.
  • 38
    Shoker BS, Jarvis C, Clarke RB et al. Abnormal regulation of the oestrogen receptor in benign breast lesions. J. Clin. Pathol. 2000; 53; 778783.
  • 39
    Gatalica Z. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol. Res. Pract. 1997; 193; 753758.
  • 40
    Tran DD, Lawson JS. Microcysts and breast cancer: a study of biological markers in archival biopsy material. Breast Cancer Res. Treat. 2002; 75; 213220.
  • 41
    Honma N, Takubo K, Akiyama F et al. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. Histopathology 2005; 47; 195201.
  • 42
    Moinfar F, Okcu M, Tsybrovskyy O et al. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 2003; 98; 703711.
  • 43
    Castiglione F, Sarotto I, Fontana V et al. Bcl2, p53 and clinical outcome in a series of 138 operable breast cancer patients. Anticancer Res. 1999; 19; 45554563.
  • 44
    Kroger N, Milde-Langosch K, Riethdorf S et al. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin. Cancer Res. 2006; 12; 159168.
  • 45
    Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br. J. Cancer 1994; 69; 135139.
  • 46
    Selim AG, El-Ayat G, Wells CA. Expression of c-erbB2, p53, Bcl-2, Bax, c-myc and Ki-67 in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast. Virchows Arch. 2002; 441; 449455.
  • 47
    Agnantis NJ, Mahera H, Maounis N, Spandidos DA. Immunohistochemical study of ras and myc oncoproteins in apocrine breast lesions with and without papillomatosis. Eur. J. Gynaecol. Oncol. 1992; 13; 309315.
  • 48
    Selim AG, El-Ayat G, Naase M, Wells CA. C-myc oncoprotein expression and gene amplification in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast. Breast 2002; 11; 466472.
  • 49
    Maitra A, Wistuba IL II, Washington C et al. High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am. J. Pathol. 2001; 159; 119130.
  • 50
    Selim AG, Ryan A, El-Ayat G, Wells CA. Loss of heterozygosity and allelic imbalance in apocrine metaplasia of the breast: microdissection microsatellite analysis. J. Pathol. 2002; 196; 287291.
  • 51
    Washington C, Dalbegue F, Abreo F, Taubenberger JK, Lichy JH. Loss of heterozygosity in fibrocystic change of the breast: genetic relationship between benign proliferative lesions and associated carcinomas. Am. J. Pathol. 2000; 157; 323329.
  • 52
    Jones C, Damiani S, Wells D, Chaggar R, Lakhani SR, Eusebi V. Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. Am. J. Pathol. 2001; 158; 207214.
  • 53
    Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406; 747752.
  • 54
    Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 2001; 98; 1086910874.
  • 55
    Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U.S.A. 2003; 100; 84188423.
  • 56
    Fan C, Oh DS, Wessels L et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 2006; 355; 560569.
  • 57
    Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J. Pathol. 2005; 205; 248254.
  • 58
    Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. U.S.A. 2003; 100; 1039310398.
  • 59
    Farmer P, Bonnefoi H, Becette V et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005; 24; 46604671.
  • 60
    Celis JE, Gromov P, Moreira JM et al. Apocrine cysts of the breast: biomarkers, origin, enlargement, and relation with cancer phenotype. Mol. Cell Proteomics 2006; 5; 462483.
  • 61
    Celis JE, Gromova I, Gromov P et al. Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia. FEBS Lett. 2006; 580; 29352944.